Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Helen Thurston"'
Autor:
Helen Thurston, Darryl Toth, Ulrich Mrowietz, Craig L. Leonardi, Charis Papavassilis, Giampiero Girolomoni, Shyamal A. Balki, Jacek C Szepietowski, Pascaline Regnault, Akimichi Morita
Background Secukinumab has demonstrated high, sustained efficacy in psoriasis to 52 weeks on a fixed-interval regimen. Objective We sought to compare a retreatment-as-needed versus a fixed-interval regimen. Methods In this double-blind study, adults
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aba29fd230f936b85108bdd317c90305
http://hdl.handle.net/11562/924990
http://hdl.handle.net/11562/924990
Publikováno v:
Headache: The Journal of Head and Face Pain. 45:1163-1170
Objective.—To evaluate the efficacy of single doses of lumiracoxib, the most selective cyclo-oxygenase (COX)-2 inhibitor, in the treatment of episodic tension-type headache (ETTH), with particular emphasis on time to onset of analgesia. Background.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b907ecc39a597076c8619879703b16e1
https://doi.org/10.1111/j.1526-4610.2005.00239.x
https://doi.org/10.1111/j.1526-4610.2005.00239.x
Autor:
E.F. Mysler, Gerhard Krammer, Stephane Litschig, G. A. Tate, Helen Thurston, A. Kreiss, T. Jung, J. Derbot, R. E. Willburger
Publikováno v:
Rheumatology (Oxford, England). 46(7)
Objectives To demonstrate non-inferiority of lumiracoxib 400 mg once daily (o.d.) compared with indomethacin 50 mg three times daily (t.i.d.) in the treatment of acute gout, and to compare the safety and tolerability of these treatments. Methods In t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::535dbc53ffca13cf2a1b062794f4017d
https://pubmed.ncbi.nlm.nih.gov/17478464
https://pubmed.ncbi.nlm.nih.gov/17478464
Autor:
Reiner Lehmann, Petr Kopsa, Stephane Litschig, Ruth Nischik, Marek Brzosko, Helen Thurston, Andreas Kreiss, Victor S. Sloan
Publikováno v:
Current medical research and opinion. 21(4)
To determine the efficacy and safety of lumiracoxib for knee osteoarthritis (OA).This was a 13-week, multicentre, randomized, double-blind, double-dummy, placebo-controlled study. Males or females aged/= 18 years with primary knee OA received lumirac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::226f85caf638e3e2722e494a17d5189d
https://pubmed.ncbi.nlm.nih.gov/15899100
https://pubmed.ncbi.nlm.nih.gov/15899100
Autor:
Helen Thurston, Hans Runge, Ulrich Trechsel, Roland Maeumbaed, Gerhard Krehan, T. Fashola, Peter Schlüter, Ralf H Wittenberg, Klaus J Burger, Ernest Schell
Publikováno v:
Arthritis Research & Therapy. 8:R35
Cyclo-oxygenase-2 selective inhibitors are frequently used to manage osteoarthritis. We compared the analgesic efficacy of the novel cyclo-oxygenase-2 selective inhibitor lumiracoxib (Prexige®) versus placebo and celecoxib in patients with knee oste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c67262ffceda76b8fd673322c9ae8c30
https://doi.org/10.1186/ar1854
https://doi.org/10.1186/ar1854